<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407952</url>
  </required_header>
  <id_info>
    <org_study_id>HEAT_protocol1</org_study_id>
    <nct_id>NCT01407952</nct_id>
  </id_info>
  <brief_title>Hydrogel Endovascular Aneurysm Treatment Trial</brief_title>
  <acronym>HEAT</acronym>
  <official_title>New Generation Hydrogel Endovascular Aneurysm Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MicroVention, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to test the effectiveness of a new generation FDA approved
      device for treating aneurysms compared to the current standard device for endovascular
      aneurysm treatment which is bare platinum coils. Endovascular procedures are a form of
      minimally invasive surgery, which is performed on blood vessels. The technique involves the
      introduction of a catheter which is a long, thin, flexible, hollow plastic tube through the
      skin into a large blood vessel. Typically the chosen blood vessel is the femoral artery found
      near the groin. The catheter is then maneuvered through the body to the location of the
      aneurysm in the brain using image guidance. Coils are delivered into the aneurysm through the
      catheters. Once the coils are delivered in the aneurysm, they are detached from the catheter.
      This is repeated until enough coils fill the aneurysm, blocking the blood flow to the
      aneurysm. The body responds by forming blood clots around the coil(s), which helps block the
      flow of blood into the aneurysm and keeps the vessel from rupturing or leaking. This study
      will compare the study device to the standard bare platinum coil to see which is better at
      preventing future rupturing or leaking. The study device is called the HydroCoil Embolization
      System and this study is a post-market clinical trial.

      About 600 subjects from multiple institutions will take part in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Your part in this study will last up to 24 months and will involve 6 visits (1 baseline visit
      before your surgery, the surgical procedure and 4 follow-up visits). These visits will occur
      at the same time as the visits you would receive as standard of care after your surgery.

      If you are in this study, you will be placed in one of two study groups by chance using a
      process similar to the flip of a coin. This process is called randomization. Neither you nor
      the study staff will select the group you will be in. One group, the control group, will have
      their aneurysm treated by the bare platinum coils during their endovascular procedure. The
      other group, the study group will receive coils from the HydroCoil Embolization System. Both
      groups will receive the same standard of care and follow-up, but during the surgery different
      types of coils will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Aneurysm Recurrence Post Surgery</measure>
    <time_frame>post surgery to 24 months</time_frame>
    <description>Defined as any progression on the Raymond-Roy (RR) Aneurysm Occlusion Scale. The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Packing Density</measure>
    <time_frame>at operation</time_frame>
    <description>Packing density as measured by volumetric filling of the aneurysm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome: Modified Rankin Scale (mRS)</measure>
    <time_frame>24 months</time_frame>
    <description>modified rankin scale is a measure of neurological disability, which ranges from 0=no symptoms to 5=severe disability (6=dead).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to the Procedure and/or the Device by Participant at Any Time in the Study.</measure>
    <time_frame>24 months</time_frame>
    <description>number of participants who experienced any peri-procedural or post-procedural Adverse Event noted to be related to the procedure or device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Peri-procedural and Post-procedural Adverse Events Related to the Procedure and/or the Device.</measure>
    <time_frame>24 months</time_frame>
    <description>total number of Adverse Events per person that were noted to be related to the procedure and device during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Expired During the Study (Mortality Rate)</measure>
    <time_frame>24 months</time_frame>
    <description>all-cause mortality at any time during study follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Initial Complete Occlusion</measure>
    <time_frame>at procedure</time_frame>
    <description>Raymond-Roy (RR) Scale=1 at procedure The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Needed Re-treatment of Target Aneurysm</measure>
    <time_frame>24 months</time_frame>
    <description>During the 24 month follow-up, if Aneurysm needed to be re-treated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Hemorrhage From Target Aneurysm Post Surgery</measure>
    <time_frame>24 months</time_frame>
    <description>Per the Adverse event log, if a hemorrhage or rupture occurred that was noted to be related to the procedure or device at any point during the 24 month follow-up (not during the operation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Progressed on the Meyers Scale</measure>
    <time_frame>24 months</time_frame>
    <description>Occlusion (in)stability was determined by progression on the Meyers scale. The Meyer scale is a 6-point grading scale based on the percentage of the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents greater than 90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, less than 25% volumetric aneurysm occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Major Versus Minor Recurrence by 24 Months Follow-up.</measure>
    <time_frame>24 months</time_frame>
    <description>Major recurrence is defined as progression on the Raymond-Roy (RR) Scale to 3, or if initial RR was 3, then progression on the Meyers scale. Minor recurrence was defined as a progression on the RR scale to 2.
The RR scale is a 3 point measure of occlusion, 1=total, 2=residual neck, and 3=residual aneurysm.
The Meyer scale is a 6-point grading scale based on the percentageof the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents &gt;90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, &lt;25% volumetric aneurysm occlusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>HydroCoil Embolic System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aneurysm treatment using bare platinum coil(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HydroCoil Embolic System</intervention_name>
    <description>HydroCoil Embolic System</description>
    <arm_group_label>HydroCoil Embolic System</arm_group_label>
    <other_name>MicroVention, Inc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control (bare platinum coils)</intervention_name>
    <description>bare platinum coils</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Candidates for this study must meet the following criteria to be enrolled in the study:

          1. Patient is between 18 and 75 years of age (inclusive).

          2. Patient has a documented untreated intracranial saccular aneurysm 3-14 mm diameter
             angiographic lumen, ruptured or unruptured, suitable for embolization with coils.

          3. Patients presenting with a HUNT and HESS Grade 0-3 or improving to such a grade before
             treatment

          4. Any type of bare platinum coils and HydroCoil 速 Coils are treatment options (all
             shapes allowed).

          5. Patient or next of kin or person with appropriate power of attorney has provided
             written informed consent.

          6. Patient is willing and available for study follow-up visits

          7. Patient has not been previously entered into this Study

        Exclusion Criteria:

        Candidates will be ineligible for enrollment in the study if any of the following
        conditions apply:

          1. Inability to obtain informed consent

          2. Patient is &lt; 18 or &gt; 75 years old

          3. Target aneurysm is not saccular in nature (mycotic, fusiform, dissecting).

          4. Target aneurysm is &gt; 14 mm maximum luminal dimension, &lt; 3 mm maximum luminal dimension

          5. Target aneurysm has been previously clipped or coiled

          6. Target aneurysm is in the physician's estimate unlikely to be successfully treated by
             endovascular techniques.

          7. Patient has known hypersensitivity to platinum, nickel, stainless steel or
             structurally related compounds found in HydroCoil速, HydroSoft速, HydroFrame速 Coils
             and/or bare platinum coils.

          8. Baseline Hunt and Hess scale 4 or 5 for ruptured aneurysms

          9. Intended use of a flow diverting stent (e.g. pipeline)

         10. Subject has concurrent intracranial pathology, e.g.

               -  Moyamoya

               -  Vasculitis documented by biopsy results

               -  AVMs

               -  AV fistulas

               -  Significant atherosclerotic disease (i.e. symptomatic and or &gt;50% narrowing of
                  the parent arteries necessary to traverse in order to coil the target aneurysm)

               -  Intracranial Hematoma (unrelated to the target aneurysm)

               -  Brain tumors

               -  Vascular tortuosity and other conditions preventing access to target aneurysm

         11. Subject has serious co-morbidities that could confound the study results:

               -  Uncontrolled hypertension

               -  Uncorrectable coagulation abnormality

               -  Contraindications for heparin, aspirin or clopidogrel

               -  Uncontrolled Diabetes Mellitus

               -  Organ failure of kidney, liver, heart, or lung

               -  Myocardial infarction within the past 6 months

               -  Cancer likely to cause death within 2 years or less.

         12. Subject history indicates high risk of non-compliance (e.g., substance abuse,
             psychosocial issues, etc.)

         13. Subject has a known history contraindicating contrast dye or iodine that cannot be
             pre-medicated prior to coiling procedure (vs. sensitivity which can be safely
             controlled by antihistamine, steroid, etc.). Medical clearance will be needed for this
             issue.

         14. Patients who are unable to complete scheduled follow up assessments at the enrolling
             center due to limited life expectancy (&lt;2 years), co-morbidities or geographical
             considerations

         15. Subject is currently breast feeding, pregnant or plans to become pregnant in the next
             2 years.

         16. Major surgical procedure or trauma within 30 days prior to randomization

         17. The patient is currently enrolled in another clinical study (device or drug).

         18. More than one aneurysm needing treatment at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard R Bendok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyerly Neurosurgery</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Health</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulting Radiologists, LTD</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health Regional Medical Center</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08638</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente NW</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>07015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hamot</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie Univerisity</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H-3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health/McMaster Univeristy</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Research Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Universtiy</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <results_first_submitted>March 31, 2019</results_first_submitted>
  <results_first_submitted_qc>June 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2019</results_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Bernard Bendok</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>treatment trial</keyword>
  <keyword>cerebral aneurysm</keyword>
  <keyword>randomized</keyword>
  <keyword>coils</keyword>
  <keyword>endovascular</keyword>
  <keyword>HEAT</keyword>
  <keyword>bare platinum</keyword>
  <keyword>Hydrogel</keyword>
  <keyword>Hydrocoil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT01407952/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HydroCoil Embolic System</title>
          <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HydroCoil Embolic System</title>
          <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="297"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="11.5"/>
                    <measurement group_id="B2" value="56.9" spread="10.3"/>
                    <measurement group_id="B3" value="56.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="490"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="490"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Aneurysm Recurrence Post Surgery</title>
        <description>Defined as any progression on the Raymond-Roy (RR) Aneurysm Occlusion Scale. The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.</description>
        <time_frame>post surgery to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Aneurysm Recurrence Post Surgery</title>
          <description>Defined as any progression on the Raymond-Roy (RR) Aneurysm Occlusion Scale. The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A intent to treat analysis was performed, using multiple imputation methods.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>3.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Chi-squared test statistic with one degree of freedom=17.37</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.99</ci_lower_limit>
            <ci_upper_limit>7.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Packing Density</title>
        <description>Packing density as measured by volumetric filling of the aneurysm</description>
        <time_frame>at operation</time_frame>
        <population>Participants with both imaging data (to determine aneurysm size), and coil information (length, number, and type used)</population>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Packing Density</title>
          <description>Packing density as measured by volumetric filling of the aneurysm</description>
          <population>Participants with both imaging data (to determine aneurysm size), and coil information (length, number, and type used)</population>
          <units>density as expressed as a percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="14.8"/>
                    <measurement group_id="O2" value="24.7" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome: Modified Rankin Scale (mRS)</title>
        <description>modified rankin scale is a measure of neurological disability, which ranges from 0=no symptoms to 5=severe disability (6=dead).</description>
        <time_frame>24 months</time_frame>
        <population>Based on participants with any post procedural follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome: Modified Rankin Scale (mRS)</title>
          <description>modified rankin scale is a measure of neurological disability, which ranges from 0=no symptoms to 5=severe disability (6=dead).</description>
          <population>Based on participants with any post procedural follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No symptoms (mRS=0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No significant disability (mRS=1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slight disability (mRS=2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate disability (mRS=3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately severe disability (mRS=4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe disability (mRS=5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Expired (mRS=6)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.578</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to the Procedure and/or the Device by Participant at Any Time in the Study.</title>
        <description>number of participants who experienced any peri-procedural or post-procedural Adverse Event noted to be related to the procedure or device.</description>
        <time_frame>24 months</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to the Procedure and/or the Device by Participant at Any Time in the Study.</title>
          <description>number of participants who experienced any peri-procedural or post-procedural Adverse Event noted to be related to the procedure or device.</description>
          <population>Intent to treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-squared test statistic with one degree of freedom = 0.865</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Peri-procedural and Post-procedural Adverse Events Related to the Procedure and/or the Device.</title>
        <description>total number of Adverse Events per person that were noted to be related to the procedure and device during the study</description>
        <time_frame>24 months</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Peri-procedural and Post-procedural Adverse Events Related to the Procedure and/or the Device.</title>
          <description>total number of Adverse Events per person that were noted to be related to the procedure and device during the study</description>
          <population>Intent to treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>One event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Two events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Three events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>Cochran-Armitage Trend Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Expired During the Study (Mortality Rate)</title>
        <description>all-cause mortality at any time during study follow-up</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Expired During the Study (Mortality Rate)</title>
          <description>all-cause mortality at any time during study follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.641</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-square test statistic with one degree of freedom=0.217</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Initial Complete Occlusion</title>
        <description>Raymond-Roy (RR) Scale=1 at procedure The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.</description>
        <time_frame>at procedure</time_frame>
        <population>Raymond-Roy Scale recorded at procedure</population>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Initial Complete Occlusion</title>
          <description>Raymond-Roy (RR) Scale=1 at procedure The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.</description>
          <population>Raymond-Roy Scale recorded at procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
            <method_desc>chi-square test statistic with one degree of freedom=8.82</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Needed Re-treatment of Target Aneurysm</title>
        <description>During the 24 month follow-up, if Aneurysm needed to be re-treated.</description>
        <time_frame>24 months</time_frame>
        <population>participants with available followup</population>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Needed Re-treatment of Target Aneurysm</title>
          <description>During the 24 month follow-up, if Aneurysm needed to be re-treated.</description>
          <population>participants with available followup</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-squared test statistic with one degree of freedom=1.955</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Hemorrhage From Target Aneurysm Post Surgery</title>
        <description>Per the Adverse event log, if a hemorrhage or rupture occurred that was noted to be related to the procedure or device at any point during the 24 month follow-up (not during the operation).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Hemorrhage From Target Aneurysm Post Surgery</title>
          <description>Per the Adverse event log, if a hemorrhage or rupture occurred that was noted to be related to the procedure or device at any point during the 24 month follow-up (not during the operation).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Progressed on the Meyers Scale</title>
        <description>Occlusion (in)stability was determined by progression on the Meyers scale. The Meyer scale is a 6-point grading scale based on the percentage of the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents greater than 90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, less than 25% volumetric aneurysm occlusion.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Progressed on the Meyers Scale</title>
          <description>Occlusion (in)stability was determined by progression on the Meyers scale. The Meyer scale is a 6-point grading scale based on the percentage of the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents greater than 90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, less than 25% volumetric aneurysm occlusion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-squared test statistic with one degree of freedom=14.743</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Major Versus Minor Recurrence by 24 Months Follow-up.</title>
        <description>Major recurrence is defined as progression on the Raymond-Roy (RR) Scale to 3, or if initial RR was 3, then progression on the Meyers scale. Minor recurrence was defined as a progression on the RR scale to 2.
The RR scale is a 3 point measure of occlusion, 1=total, 2=residual neck, and 3=residual aneurysm.
The Meyer scale is a 6-point grading scale based on the percentageof the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents &gt;90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, &lt;25% volumetric aneurysm occlusion.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HydroCoil Embolic System</title>
            <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Major Versus Minor Recurrence by 24 Months Follow-up.</title>
          <description>Major recurrence is defined as progression on the Raymond-Roy (RR) Scale to 3, or if initial RR was 3, then progression on the Meyers scale. Minor recurrence was defined as a progression on the RR scale to 2.
The RR scale is a 3 point measure of occlusion, 1=total, 2=residual neck, and 3=residual aneurysm.
The Meyer scale is a 6-point grading scale based on the percentageof the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents &gt;90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, &lt;25% volumetric aneurysm occlusion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Major recurrence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minor recurrence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No major/minor recurrence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected until 18-24 month visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HydroCoil Embolic System</title>
          <description>Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
HydroCoil Embolic System: HydroCoil Embolic System</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Aneurysm treatment using bare platinum coil(s)
Control (bare platinum coils): bare platinum coils</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy, non-schemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hemianopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Scotoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture left-femur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Aneurysm, left ICA ophthalmic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Hemorrhage, intraventicular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm, ruptured</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage, non-specified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage, subarachnoid</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intracranial, hemorrhage, subdural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intracranial hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Memory loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Parasthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Transient ischemic attach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral salt wasting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Coil herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Coil prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Groin hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Procedural Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Psedudoaneurysm, cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Retroperitonial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Disturbance</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>All other adverse events that did not meet the 3% threshold individually. (e.g. Anemia, Dyspnea, Rash)</description>
                <counts group_id="E1" events="105" subjects_affected="70" subjects_at_risk="297"/>
                <counts group_id="E2" events="111" subjects_affected="86" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="49" subjects_affected="38" subjects_at_risk="297"/>
                <counts group_id="E2" events="53" subjects_affected="50" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Parasthesia</sub_title>
                <description>Numbness in face, arms, legs</description>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard Bendok, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>3129269441</phone>
      <email>bendok.bernard@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

